Reinventing the ASCO Educational Book to Capture the Advances in Oncology Year-Round [0.03%]
重塑ASCO教育用书以全面覆盖肿瘤学年度进展
Gerald Hsu
Gerald Hsu
Advances in Systemic Therapies for Rare Head and Neck Malignancies: Spotlight on Adenoid Cystic Carcinoma, Differentiated Thyroid Cancer, and Sinonasal/Paranasal Tumors [0.03%]
罕见头颈部恶性肿瘤的系统性治疗进展：腺样囊性癌、分化型甲状腺癌和鼻窦/鼻旁窦肿瘤的研究焦点
Thomas J Roberts,Bhumsuk Keam,Nyall R London Jr et al.
Thomas J Roberts et al.
Rare head and neck cancers, including adenoid cystic carcinoma (ACC), differentiated thyroid cancer (DTC), and sinonasal/paranasal tumors, represent a diverse pathology with shared clinical challenges, including heterogenous biology and lim...
Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma [0.03%]
一踩油门一刹车——刺激诱发的黑色素瘤治疗体系
Afsaneh Amouzegar,Reid Shaw,Katy K Tsai et al.
Afsaneh Amouzegar et al.
Immunotherapy and BRAF-targeted therapy strategies reduce recurrence risk and improve survival in patients with high-risk resected and metastatic melanoma, respectively. Optimizing the use of these treatment options can maximize clinical be...
Navigating Multimodality Therapy in Non-Small Cell Lung Cancer: Neoadjuvant-Only Versus Perioperative Immunotherapy, Surgical Imperatives, and Future Approaches [0.03%]
非小细胞肺癌多模式治疗导航：新辅助免疫治疗与围手术期免疫治疗、外科手术指征及未来策略
Gökce Yavuz,Michael Wang,Jonathan D Spicer et al.
Gökce Yavuz et al.
Neoadjuvant and perioperative immunotherapy have redefined the treatment landscape for select patients with early-stage and locally-advanced resectable non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors targeting the PD-1/PD-L...
John W J Pottow,Patricia Mae Garcia Santos
John W J Pottow
Immigrants comprise a substantial and growing proportion of the US population, yet they face profound barriers to timely, affordable, and high-quality cancer care. These barriers are shaped not only by language, culture, and health literacy...
Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies [0.03%]
神经内分泌肿瘤的治疗策略演变：个性化治疗的新时代
Udhayvir S Grewal,Shagufta Shaheen,David B Zhen et al.
Udhayvir S Grewal et al.
Neuroendocrine neoplasms (NENs) represent a heterogeneous group of malignancies ranging from relatively indolent well-differentiated neuroendocrine tumors (NETs) to more aggressive poorly differentiated neuroendocrine carcinomas (NECs). The...
Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum [0.03%]
多阶段，一事业——运用职业发展计划在学术肿瘤学各发展阶段取得成功与满足感
Brian M Russell,Richard D Hall,Kristin J Redmond et al.
Brian M Russell et al.
Oncology-trained physicians-including medical oncologists, radiation oncologists, and surgical oncologists-can pursue a diverse set of career paths. However, with increasing concerns about physicians moving away from the path of academic on...
Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications [0.03%]
免疫检查点阻断疗法：更多联合用药和更少的禁忌症
Justine V Cohen,Adam Adika,Matthew Zibelman et al.
Justine V Cohen et al.
Immune checkpoint inhibitors (ICIs) have transformed the treatment of a broad range of malignancies over the past decade. As the scope of indications and the clinical experience expands, oncologists are increasingly confronted with complex ...
Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer [0.03%]
早期可手术非小细胞肺癌靶向治疗和免疫治疗的合理应用
Raymond U Osarogiagbon,Jeremy P Cetnar,Raid Aljumaily
Raymond U Osarogiagbon
As systemic therapies for non-small cell lung cancer (NSCLC) have become more effective, interest in their use for improving long-term surgical outcomes has rapidly increased. Imperfect as it is, stage remains the primary means for identify...
Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies [0.03%]
赛前的干预：预防儿童癌症治疗长期后遗症不容忽视
Etan Orgel,Karen C Burns,Joshua Gorlick et al.
Etan Orgel et al.
Increasing treatment intensity has improved survival rates for children with cancer, resulting in an increasing population burdened with late effects from treatment. The Children's Oncology Group Survivorship Guidelines provide a compendium...